Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report 2

01. Comments on the Appraisal Consultation Document from the manufacturer, Astellas

02. Prostate Cancer UK

03. Prostate Cancer Support Federation

04. British Uro-oncology Group

05. Royal College of Nursing

06. Royal College of Physicians

07. Department of Health

08. Janssen

09. Stuart Watson

10. Comments on the Appraisal Consultation Document received through the NICE website

11. Evidence Review Group critique

12. Evidence Review Group critique - addendum

* Users experiencing difficulty opeing the document should save it first (right click, save target as) before opeing in Adobe Reader or Acrobat*